Geode Capital Management
TNGX icon

Geode Capital Management’s Tango Therapeutics TNGX Stock Holding History

Geode Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117M Buy
3,742,791
+1,067,014
+40% +$26.4M 0.01% 1088
2026
Q1 		$56M Buy
2,675,777
+122,121
+5% +$1.7M ﹤0.01% 1432
2025
Q4 		$22.6M Buy
2,553,656
+670,879
+36% +$5.78M ﹤0.01% 1936
2025
Q3 		$15.8M Buy
1,882,777
+113,864
+6% +$771K ﹤0.01% 2128
2025
Q2 		$9.06M Buy
1,768,913
+385,476
+28% +$953K ﹤0.01% 2426
2025
Q1 		$1.9M Sell
1,383,437
-3,012
-0.2% -$7.4K ﹤0.01% 3055
2024
Q4 		$4.29M Buy
1,386,449
+18,187
+1% +$84.4K ﹤0.01% 2815
2024
Q3 		$10.5M Buy
1,368,262
+142,710
+12% +$1.36M ﹤0.01% 2347
2024
Q2 		$10.5M Buy
1,225,552
+92,017
+8% +$711K ﹤0.01% 2293
2024
Q1 		$9M Buy
1,133,535
+36,433
+3% +$391K ﹤0.01% 2387
2023
Q4 		$10.9M Buy
1,097,102
+62,108
+6% +$539K ﹤0.01% 2297
2023
Q3 		$11.7M Buy
1,034,994
+96,157
+10% +$586K ﹤0.01% 2165
2023
Q2 		$3.12M Buy
938,837
+51,966
+6% +$187K ﹤0.01% 2950
2023
Q1 		$3.5M Buy
886,871
+34,503
+4% +$200K ﹤0.01% 2790
2022
Q4 		$6.18M Buy
852,368
+12,605
+2% +$88.7K ﹤0.01% 2547
2022
Q3 		$3.04M Sell
839,763
-150,737
-15% -$644K ﹤0.01% 2935
2022
Q2 		$4.49M Buy
990,500
+397,158
+67% +$2.4M ﹤0.01% 2756
2022
Q1 		$4.5M Buy
593,342
+6,165
+1% +$53.4K ﹤0.01% 2854
2021
Q4 		$6.42M Buy
587,177
+158,542
+37% +$1.91M ﹤0.01% 2746
2021
Q3 		$5.54M Buy
428,635
+414,626
+2,960% +$4.97M ﹤0.01% 2847
2021
Q2 		$159K Buy
+14,009
New +$157K ﹤0.01% 4423

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Geode Capital Management's TNGX Position: Q2 2026 in Review

Geode Capital Management increased its Tango Therapeutics (TNGX) stake by 40% in Q2 2026, buying an estimated $26.4M and bringing the position to 3,742,791 shares worth $117M. The position accounts for 0.01% of the portfolio, ranked #1088.

Geode Capital Management first reported a position in TNGX in Q2 2021 and has held it in 21 quarters since. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Geode Capital Management held 3,742,791 shares of Tango Therapeutics worth $117M as of Q2 2026.
  • Geode Capital Management bought 1,067,014 Tango Therapeutics shares in Q2 2026, an estimated $26.4M.
  • Tango Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #1088 holding.
  • Geode Capital Management first reported a position in Tango Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.